This document explains the VeDDRA terminology for reporting adverse reactions in animals and humans, providing guidelines on selecting appropriate terms at the Lowest Level Term (LLT) level, changes to System of Controls (SOCs), and specific coding for cases like death and anaphylaxis. It outlines the four-level hierarchical structure of VeDDRA and distinguishes between clinical signs, emphasizing the correct use of LLT terms.
The guidance highlights the importance of using the LLT 'Death' term for reporting adverse events, the LLT 'Unrelated Death' term for anaphylaxis, and LLT terms for local reactions at application, injection, or implantation sites. It also covers the appropriate use of LLT terms for various clinical signs, including ear and labyrinth disorders, pain and discomfort.
Recent updates to the document include new sections on anaphylaxis, hypersensitivity reactions, and information on suspected infectious agent transmission, reversal to virulence, transmission of a vaccine strain, recombination of a vaccine strain, and prolonged shedding of a vaccine strain.
Region: European Union
Reach out to us and let’s unravel your Regulatory puzzle together. Unlock regulatory solutions with our global subject matter experts and tap into a wealth of regulatory intelligence.
Speak to an ExpertSay goodbye to hours spent on Regulatory research, with our AI powered Regulatory Advisor. Get verified Regulatory information from Health authorities across 150+ countries.
Unlock efficiency with Freya,
your Regulatory time saver!